The markets opened mixed with the Dow gaining 56 points to 15,171 while Nasdaq lost 9 points to 3446 as April construction spending edged up 0.4%.
On the upside
Peregrine Pharmaceuticals (Nasdaq: PPHM) reported upbeat interim results from a Phase I study of bavituximab in treating breast cancer and positive results from a Phase II trial in pancreatic cancer patients.
Merck & Co. (NYSE: MRK) presented preliminary results from a Phase IB study of its advanced melanoma treatment lambrolizumab and expects to begin late stage trials in the third quarter of 2013.
On the downside
Affymax (Nasdaq: AFFY) will be delisted from Nasdaq after market close on Wednesday.
Synta Pharmaceuticals (Nasdaq: SNTA) reported interim results from a Phase 2b/3 study of its lung cancer treatment that were not statistically significant.
Infinity Pharmaceuticals (Nasdaq: INFI) updated data from an ongoing Phase I study of its chronic lymphocytic leukemia treatment IPI-145.
In the broad market, declining issues outpaced advancers by a margin of nearly 10 to 9 on the NYSE and by 5 to 3 on Nasdaq. The broader S&P 500 index held steady at 1630.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here